Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of pegylated recombinant human growth hormone injection in children with short stature due to being born small for gestational age
CTR20254162Phase 2Active
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of peg-somatropin, somatropin in growth disorder, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Started Nov 2025; status: active.
02
Drugs
peg-somatropinsomatropin
03
Conditions
growth disorder
Beyond the preview
Go deeper on CTR20254162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254162.